Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program

Saved in:
Bibliographic Details
Published inDiabetes, obesity & metabolism Vol. 24; no. 12; pp. 2459 - 2464
Main Authors Nunes, Julio C., Yu, Jie, Arnott, Clare, Jardine, Meg J., Perkovic, Vlado, Mahaffey, Kenneth W.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.12.2022
Wiley Subscription Services, Inc
Subjects
antidiabetic drug
Antidiabetics
canagliflozin
Canagliflozin - adverse effects
Cardiovascular Diseases - chemically induced
clinical trial
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 2 - chemically induced
Diabetes Mellitus, Type 2 - drug therapy
drug development
Drug therapy
Humans
Mental disorders
Mental Health
Side effects
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
clinical trial
antidiabetic drug
drug development
canagliflozin
Online AccessGet full text

Cover

More Information
Bibliography:Funding information
The CREDENCE (NCT02065791), CANVAS (NCT01032629) and CANVAS‐R (NCT01989754) clinical trials, which are the basis of this study, were sponsored by Janssen Research and Development. This post hoc analysis was not specifically funded. The funders were not involved in the design, analysis, reporting or decision to submit this manuscript for publication.
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.14832